Group 1 - The company reported a revenue of approximately 489 million RMB and a net profit of about 4.06 million RMB for the first half of 2025, with a positive net cash flow from operating activities of 34.83 million RMB, representing a 25% year-on-year increase [1] - Since its strategic transformation to CDMO, the company has become a leading domestic biopharmaceutical CDMO provider, offering comprehensive international services from R&D to commercial production for various bioconjugates [1] - As of June 30, 2025, the company added 16 new projects in the first half of the year, including 14 ADC projects, bringing the total to 169 projects, and assisted 12 projects in advancing from preclinical to clinical stages, showcasing its service delivery capabilities [1] - The company has signed uncompleted orders amounting to 200 million RMB, with a repurchase rate of 73% due to its excellent delivery capabilities and service quality [1] - The company successfully assisted clients in completing the world's first approved clinical dual-load ADC project during the reporting period [1] Group 2 - The company's core product, Bevacizumab injection (domestic brand name: Puxintin®), has made significant progress in overseas expansion in emerging markets, successfully obtaining market approval from regulatory authorities in Nigeria and Pakistan in the first half of 2025 [2] - Facilities related to the product have passed GMP inspections in Brazil, Colombia, Egypt, Indonesia, Argentina, and Pakistan, indicating international recognition of the company's quality system and compliance [2] - The approvals in Nigeria and Pakistan mark a breakthrough for the company in international commercial supply, as it will be responsible for the global commercialization of Bevacizumab injection [2]
东曜药业-B(01875)上半年CDMO技术领跑行业 核心产品全球化布局实现突破